Enbumyst is a drug owned by Corstasis Therapeutics Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 04, 2040. Details of Enbumyst's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11123319 | NA |
Dec, 2040
(15 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Enbumyst is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Enbumyst's family patents as well as insights into ongoing legal events on those patents.
Enbumyst's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Enbumyst's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 04, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Enbumyst Generic API suppliers:
Bumetanide is the generic name for the brand Enbumyst. 20 different companies have already filed for the generic of Enbumyst, with Amneal Pharms Co having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Enbumyst's generic
About Enbumyst
Enbumyst is a drug owned by Corstasis Therapeutics Inc. Enbumyst uses Bumetanide as an active ingredient. Enbumyst was launched by Corstasis Therap in 2025.
Approval Date:
Enbumyst was approved by FDA for market use on 12 September, 2025.
Active Ingredient:
Enbumyst uses Bumetanide as the active ingredient. Check out other Drugs and Companies using Bumetanide ingredient
Dosage:
Enbumyst is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5MG/SPRAY | SPRAY | Prescription | NASAL |